If enacted, lawmakers will hold the right to monitor and restrict American companies from signing certain deals with Chinese entities.
Lilly’s deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines.
The partnership brings together CytomX’s biologic masking technology and Regeneron’s expertise in bispecific antibodies.
Under the agreement, Cellares will use its Cell Shuttle and Cell Q systems to automate TSC-101 manufacturing processes.
The Google Ventures-backed company could become the first to commercialise a reversible male contraceptive drug, provided the gel is successful in Phase III.
A decision from the FDA is anticipated by 30 November 2026.
